Cancer Biomarkers Development and Clinical Use

Monday, June 16, 2008 
at 
The Yale Club of New York City
located at
50 Vanderbilt Avenue directly across the street from Grand Central Station
between East 44th Street and East 45th Street
(one block east of Madison Avenue)
New York, New York, U.S.A. 10017

Overview:

The TriMark Cancer Biomarkers 2008 Conference has been organized to provide a critical examination of the latest in cancer diagnosis, as well as to provide insight from key industry leaders concerning cutting-edge technology platforms. This conference will also provide a forum for leaders in cancer biomarkers to share ideas, network with other delegates and advance understanding of the potential of new cancer detection technologies.

Who Should Attend:

• Cancer diagnostics company representatives.
• In vitro diagnostic companies management and R&D directors.
• Biotechnology companies.
• Medical devices manufacturers. 
• Diagnostic laboratory directors and staff.

Leaders from the Following Areas Will Greatly Benefit from Attending:

• Clinical Laboratory leaders.
• Hospital CFOs and CSOs.
• Physicians.
• Cancer diagnostics developers.
• Business development leaders.
• Strategic planning and development personnel.
• Technology development. 
• Marketing. 
• Research and development. 

Key Themes:

• A critical examination of key emerging biomarker technologies for cancer diagnostics. 
• Formation of successful alliances. 
• Application of emerging technologies to cancer diagnostics. 
• Transitioning from laboratory in vitro diagnostics to clinical management of cancer patients. 
• The emerging role of cancer diagnostic tests in personalized medicine.
• The intersection of genomics and cancer diagnostics with personalized medicine.

Questions Answered in the TriMark Conference:

• What will the cancer diagnostics market be worth by the end of the decade? 
• Which market key segments will drive cancer diagnostics market growth? 
• Which new technologies will reach the cancer diagnostics market in the next 2-3 years? 
• How is technology innovation impacting the dynamics and direction of the diagnostics industry? 
• How can clinical labs bring new cancer diagnostic tests to patent care?
• What are the key challenges in gaining acceptance of new technologies by users, payers and regulators? 
• How is technology innovation facilitating the transition of new cancer diagnostics testing into standard healthcare practice? 

Top Five Reasons To Attend the TriMark Conference:

• Discover the cancer biomarkers sectors with the greatest prospective growth, ensuring you can successfully align your future strategies with predicted success. 
• Evaluate the competitive dynamics of the cancer biomarkers market and understand the changing relationship between IVD companies and the cancer diagnostics testing sector. 
• Identify the key players in the cancer biomarkers market, recognize lucrative partnering opportunities and benchmark your strategies against the leading players. 
• Assess opportunities and challenges faced by diagnostic companies in gaining acceptance of innovative technologies by payers, regulators and users. 
• Understand the factors driving growth of the cancer biomarkers market.